Yellowstone Biosciences

Yellowstone Biosciences is a therapeutic biotechnology company dedicated to developing highly selective cancer-targeted therapies. The company aims to create a new class of therapeutic target antigens that are frequently expressed and have the potential to significantly transform patients' lives. Utilizing its exclusive biobank of primary samples from acute myeloid leukemia (AML) patients, Yellowstone designs bispecific T-cell engagers based on T-cell receptors (TCR) for the treatment of a range of currently incurable cancers. Leveraging this proprietary biobank and world-class protein engineering capabilities, Yellowstone is advancing its leading program in acute myeloid leukemia (AML) and has the potential to expand research and development into a series of other common cancers exhibiting human leukocyte antigen (HLA) class II expression.